What question did this study set out to answer?

Assess the real-world efficacy and tolerability of teclistamab in patients with relapsed and refractory multiple myeloma to determine whether outcomes match pivotal clinical trial results.

January 20, 2024LeukemiaOpen Access

Real-world analysis of teclistamab in 123 RRMM patients from Germany

View Full Paper

Ask AI

Bookmark

Authors

CRChristine RiedhammerUniversity of Würzburg FBFlorian BassermannKlinikum rechts der Isar BBBritta BesemerUniversity Children's Hospital Tübingen

Discussion

Member takes

Implication

Retrospective cohort study reveals efficacy of teclistamab in relapsed and refractory multiple myeloma, confirming clinical trial benefits despite reduced survival in high-risk subgroups.

Key Points

Assess the real-world efficacy and tolerability of teclistamab in patients with relapsed and refractory multiple myeloma to determine whether outcomes match pivotal clinical trial results.
Retrospective multicenter study evaluating N=123 patients treated with teclistamab across 18 centers in Germany.
Included heavily pretreated patients: 93% triple-class refractory, 60% penta-drug refractory, and 37% exposed to prior anti-BCMA therapy (including 17.1% post-idecabtagene vicleucel).
Monitored clinical response rates, progression-free survival, and treatment-related adverse events over a median follow-up of 5.5 months.
The overall cohort achieved an overall response rate of 59.3% and a median progression-free survival of 8.7 months.
Significantly poorer outcomes occurred in patients with extramedullary disease (overall response rate 37%, median progression-free survival 2.1 months), ISS stage 3 (37%, 1.3 months), and prior ide-cel therapy (33%, 1.8 months).
Adverse events were predominantly characterized by infections and grade ≥3 cytopenias, while response duration in prior ide-cel recipients remained similar to anti-BCMA-naive individuals.

Cite This Study

Riedhammer et al. (2024) studied this question.

synapsesocial.com/papers/69dc2bd63080d3567e274584 https://doi.org/10.1038/s41375-024-02154-5

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study reveals efficacy of teclistamab in relapsed and refractory multiple myeloma, confirming clinical trial benefits despite reduced survival in high-risk subgroups.

Real-world analysis of teclistamab in 123 RRMM patients from Germany

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-world analysis of teclistamab in 123 RRMM patients from Germany

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider